SCHEMBL7063019

SCHEMBL7063019

Cc1cc(NC(=O)C(=O)OC(C)C)cc(C)c1Oc1ccc(O)c(S(=O)(=O)c2ccc(F)cc2)c1

nearest known ligand 0.55

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
THRA P10827 7/20 0.55
THRB P10828 7/20 0.55
CNR1 P21554 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7063675 0.94 THRA (0.49) THRATHRB
SCHEMBL7061490 0.91 THRA (0.56) THRATHRBCNR1
SCHEMBL7061235 0.90 THRA (0.44) THRATHRBCNR1
SCHEMBL6661895 0.89 THRA (0.67) THRATHRB
SCHEMBL6738408 0.88 THRA (0.51) THRATHRBCNR1
SCHEMBL1642407 0.88 THRA (0.58) THRATHRB
SCHEMBL6742192 0.87 THRA (0.52) THRATHRB
SCHEMBL1640506 0.85 THRA (0.48) THRATHRBCNR1
SCHEMBL7061428 0.84 THRA (0.50) THRATHRB
SCHEMBL1642411 0.83 THRA (0.49) THRATHRBCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030114521-A1 Oxamic acids and derivatives as thyroid receptor ligands CHIANG YUAN-CHING PHOEBE (US) 2003-06-19 US claimed
US-6545018-B2 Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis PFIZER INC. 2003-04-08 US claimed
US-20020049226-A1 Oxamic acids and derivatives as thyroid receptor ligands CHIANG YUAN-CHING PHOEBE (US) 2002-04-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114521-A1 Oxamic acids and derivatives as thyroid receptor ligands OXER1, THRA, TSHR THRA 2/4885THRB 4/4885CNR1 373/4885
US-20020049226-A1 Oxamic acids and derivatives as thyroid receptor ligands OXER1, THRA, OXGR1 THRA 2/4885THRB 4/4885CNR1 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.